EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

  • Li Wang
  • , Abdel Saci
  • , Peter M. Szabo
  • , Scott D. Chasalow
  • , Mireia Castillo-Martin
  • , Josep Domingo-Domenech
  • , Arlene Siefker-Radtke
  • , Padmanee Sharma
  • , John P. Sfakianos
  • , Yixuan Gong
  • , Ana Dominguez-Andres
  • , William K. Oh
  • , David Mulholland
  • , Alex Azrilevich
  • , Liangyuan Hu
  • , Carlos Cordon-Cardo
  • , Hélène Salmon
  • , Nina Bhardwaj
  • , Jun Zhu
  • , Matthew D. Galsky

Research output: Contribution to journalArticlepeer-review

239 Scopus citations

Abstract

Cancers infiltrated with T-cells are associated with a higher likelihood of response to PD-1/PD-L1 blockade. Counterintuitively, a correlation between epithelial–mesenchymal transition (EMT)-related gene expression and T-cell infiltration has been observed across tumor types. Here we demonstrate, using The Cancer Genome Atlas (TCGA) urothelial cancer dataset, that although a gene expression-based measure of infiltrating T-cell abundance and EMT-related gene expression are positively correlated, these signatures convey disparate prognostic information. We further demonstrate that non-hematopoietic stromal cells are a major source of EMT-related gene expression in bulk urothelial cancer transcriptomes. Finally, using a cohort of patients with metastatic urothelial cancer treated with a PD-1 inhibitor, nivolumab, we demonstrate that in patients with T-cell infiltrated tumors, higher EMT/stroma-related gene expression is associated with lower response rates and shorter progression-free and overall survival. Together, our findings suggest a stroma-mediated source of immune resistance in urothelial cancer and provide rationale for co-targeting PD-1 and stromal elements.

Original languageEnglish
Article number3503
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - 1 Dec 2018

Fingerprint

Dive into the research topics of 'EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer'. Together they form a unique fingerprint.

Cite this